Removing B2m with Nanobodies
Among those on dialysis, a build up in the blood of Beta-2 microglobulin (B2m) is responsible for potentially crippling dialysis-related amyloidosis (DRA). Nanobodies are functional antibody fragments—and, used in a resin, they captured 17 times more B2m than in earlier studies, without affecting other blood proteins. Even better, the resin can be regenerated and used again. One day, this approach may be combined with dialysis to improve treatments.
Read the full article » | Posted 03-16-2020
Related Articles
- The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
- Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026
- Byonyks on the Move: X-2 and X-3 APD Devices in Development Posted 07-16-2026
- Dr. Ben Reynolds and the Virtual Reality Kidney Dialysis Training Project Posted 06-17-2026

